{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:41:27Z","timestamp":1791477687575,"version":"4.3.4"},"reference-count":149,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) is frequently associated with metabolic disorders, being highly prevalent in obese and diabetic patients. Many concomitant factors that promote systemic and liver inflammation are involved in NAFLD pathogenesis, with a growing body of evidence highlighting the key role of the gut microbiota. Indeed, the gut-liver axis has a strong impact in the promotion of NAFLD and in the progression of the wide spectrum of its manifestations, claiming efforts to find effective strategies for gut microbiota modulation. Diet is among the most powerful tools; Western diet negatively affects intestinal permeability and the gut microbiota composition and function, selecting pathobionts, whereas Mediterranean diet fosters health-promoting bacteria, with a favorable impact on lipid and glucose metabolism and liver inflammation. Antibiotics and probiotics have been used to improve NAFLD features, with mixed results. More interestingly, medications used to treat NAFLD-associated comorbidities may also modulate the gut microbiota. Drugs for the treatment of type 2 diabetes mellitus (T2DM), such as metformin, glucagon-like peptide-1 (GLP-1) agonists, and sodium-glucose cotransporter (SGLT) inhibitors, are not only effective in the regulation of glucose homeostasis, but also in the reduction of liver fat content and inflammation, and they are associated with a shift in the gut microbiota composition towards a healthy phenotype. Even bariatric surgery significantly changes the gut microbiota, mostly due to the modification of the gastrointestinal anatomy, with a parallel improvement in histological features of NAFLD. Other options with promising effects in reprogramming the gut-liver axis, such as fecal microbial transplantation (FMT) and next-generation probiotics deserve further investigation for future inclusion in the therapeutic armamentarium of NAFLD.<\/jats:p>","DOI":"10.3389\/fnut.2023.1110536","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T10:30:28Z","timestamp":1676543428000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":71,"title":["Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies"],"prefix":"10.3389","volume":"10","author":[{"given":"Marta","family":"Maestri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Santopaolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pompili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Ponziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11901-016-0295-9","article-title":"Extrahepatic manifestations of nonalcoholic fatty liver disease.","volume":"15","author":"VanWagner","year":"2016","journal-title":"Curr Hepatol Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease.","volume":"64","year":"2016","journal-title":"J Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease.","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"International consensus panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.07.045","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade.","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy.","volume":"72","author":"Albillos","year":"2020","journal-title":"J Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease.","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab."},{"key":"B11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1499-3872(17)60019-5","article-title":"Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.","volume":"16","author":"Shen","year":"2017","journal-title":"Hepatobiliary Pancreat Dis Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cmet.2020.06.005","article-title":"A universal gut-microbiome-derived signature predicts cirrhosis.","volume":"32","author":"Oh","year":"2020","journal-title":"Cell Metab."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/nu9111220","article-title":"Nonalcoholic fatty liver disease is exacerbated in high-fat diet-fed gnotobiotic mice by colonization with the gut microbiota from patients with nonalcoholic steatohepatitis.","volume":"9","author":"Chiu","year":"2017","journal-title":"Nutrients."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01751-y","article-title":"Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota.","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.","volume":"71","author":"Mouries","year":"2019","journal-title":"J Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","article-title":"Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial.","volume":"115","author":"Craven","year":"2020","journal-title":"Am J Gastroenterol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33893-y","article-title":"Fecal microbiota transplantation confers beneficial metabolic effects of diet and exercise on diet-induced obese mice.","volume":"8","author":"Lai","year":"2018","journal-title":"Sci Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/17474124.2018.1481747","article-title":"Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications.","volume":"12","author":"Ponziani","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.571731","article-title":"Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes.","volume":"11","author":"Scheithauer","year":"2020","journal-title":"Front Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.22034","article-title":"Liver: an organ with predominant innate immunity.","volume":"47","author":"Gao","year":"2008","journal-title":"Hepatology."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph182312836","article-title":"Intestinal barrier in human health and disease.","volume":"18","author":"Di Tommaso","year":"2021","journal-title":"Int J Environ Res Public Health."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.3748\/wjg.v25.i33.4814","article-title":"Intestinal permeability in the pathogenesis of liver damage: from non-alcoholic fatty liver disease to liver transplantation.","volume":"25","author":"Nicoletti","year":"2019","journal-title":"World J Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jhep.2007.04.019","article-title":"Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis.","volume":"47","author":"Rivera","year":"2007","journal-title":"J Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2010.03.052","article-title":"Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice.","volume":"139","author":"Miura","year":"2010","journal-title":"Gastroenterology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.diabres.2014.04.006","article-title":"Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes.","volume":"105","author":"Esser","year":"2014","journal-title":"Diabetes Res Clin Pract."},{"key":"B26","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1017\/S0007114512005119","article-title":"A consideration of biomarkers to be used for evaluation of inflammation in human nutritional studies.","author":"Calder","year":"2013","journal-title":"Br J Nutr."},{"key":"B27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.15403\/jgld-197","article-title":"Effects of dietary intervention on gut microbiota and metabolic-nutritional profile of outpatients with non-alcoholic steatohepatitis: a randomized clinical trial.","volume":"28","author":"Ghetti","year":"2019","journal-title":"J Gastrointest Liver Dis."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/nu13010007","article-title":"Influence of mediterranean diet on human gut microbiota.","volume":"13","author":"Merra","year":"2020","journal-title":"Nutrients."},{"key":"B29","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3945\/ajcn.113.079277","article-title":"Dietary determinants of hepatic steatosis and visceral adiposity in overweight and obese youth at risk of type 2 diabetes.","volume":"99","author":"Mollard","year":"2014","journal-title":"Am J Clin Nutr."},{"key":"B30","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3945\/ajcn.112.038695","article-title":"Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans.","volume":"96","author":"Sevastianova","year":"2012","journal-title":"Am J Clin Nutr."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-018-0307-8","article-title":"Dietary fat stimulates development of NAFLD more potently than dietary fructose in Sprague-Dawley rats.","volume":"10","author":"Jensen","year":"2018","journal-title":"Diabetol Metab Syndr."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.2337\/dc19-2331","article-title":"Intrahepatic fat and postprandial glycemia increase after consumption of a diet enriched in saturated fat compared with free sugars.","volume":"43","author":"Parry","year":"2020","journal-title":"Diabetes Care."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/nu14153186","article-title":"Adherence to mediterranean diet and NAFLD in patients with metabolic syndrome: the FLIPAN study.","volume":"14","author":"Montemayor","year":"2022","journal-title":"Nutrients."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/nu11102543","article-title":"The metabolic and hepatic impact of two personalized dietary strategies in subjects with obesity and nonalcoholic fatty liver disease: the fatty liver in obesity (FLiO) randomized controlled trial.","volume":"11","author":"Marin-Alejandre","year":"2019","journal-title":"Nutrients."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1136\/gutjnl-2020-323106","article-title":"Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial.","volume":"70","author":"Yaskolka Meir","year":"2021","journal-title":"Gut."},{"key":"B36","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41591-020-01223-3","article-title":"The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk.","volume":"27","author":"Wang","year":"2021","journal-title":"Nat Med."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/nu10111793","article-title":"Gut permeability might be improved by dietary fiber in individuals with nonalcoholic fatty liver disease (NAFLD) undergoing weight reduction.","volume":"10","author":"Krawczyk","year":"2018","journal-title":"Nutrients."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/nu12103100","article-title":"Microbiota, fiber, and NAFLD: is there any connection?","volume":"12","author":"P\u00e9rez-Montes de Oca","year":"2020","journal-title":"Nutrients."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.861854","article-title":"Amelioratory effect of resistant starch on non-alcoholic fatty liver disease via the gut-liver axis.","volume":"9","author":"Zhu","year":"2022","journal-title":"Front Nutr."},{"key":"B40","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1146\/annurev-immunol-051116-052235","article-title":"Metabolite-sensing G protein-coupled receptors-facilitators of diet-related immune regulation.","volume":"35","author":"Tan","year":"2017","journal-title":"Annu Rev Immunol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.567654","article-title":"Microbial metabolites: critical regulators in NAFLD.","volume":"11","author":"Dai","year":"2020","journal-title":"Front Microbiol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-021-01125-7","article-title":"Commensal microbe-derived acetate suppresses NAFLD\/NASH development via hepatic FFAR2 signalling in mice.","volume":"9","author":"Aoki","year":"2021","journal-title":"Microbiome."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02546-x","article-title":"Colonic infusions of short-chain fatty acid mixtures promote energy metabolism in overweight\/obese men: a randomized crossover trial.","volume":"7","author":"Canfora","year":"2017","journal-title":"Sci Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1136\/gutjnl-2014-307913","article-title":"Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults.","volume":"64","author":"Chambers","year":"2015","journal-title":"Gut."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1017\/S0007114515003621","article-title":"Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH).","volume":"114","author":"Jin","year":"2015","journal-title":"Br J Nutr."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01159","article-title":"Fructose: a dietary sugar in crosstalk with microbiota contributing to the development and progression of non-alcoholic liver disease.","volume":"8","author":"Lambertz","year":"2017","journal-title":"Front Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","article-title":"Fructose and sugar: a major mediator of non-alcoholic fatty liver disease.","volume":"68","author":"Jensen","year":"2018","journal-title":"J Hepatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.jhep.2008.01.035","article-title":"Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin.","volume":"48","author":"Bergheim","year":"2008","journal-title":"J Hepatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.clnu.2015.01.021","article-title":"Effect of specific amino acids on hepatic lipid metabolism in fructose-induced non-alcoholic fatty liver disease.","volume":"35","author":"Jegatheesan","year":"2016","journal-title":"Clin Nutr."},{"key":"B50","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3945\/jn.116.242859","article-title":"Intestinal barrier function and the gut microbiome are differentially affected in mice fed a western-style diet or drinking water supplemented with fructose.","volume":"147","author":"Volynets","year":"2017","journal-title":"J Nutr."},{"key":"B51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1017\/S0007114516001793","article-title":"Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats.","volume":"116","author":"Jegatheesan","year":"2016","journal-title":"Br J Nutr."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080169","article-title":"Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice.","volume":"9","author":"Ritze","year":"2014","journal-title":"PLoS One."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1080\/16546628.2017.1331657","article-title":"Dietary fructose causes defective insulin signalling and ceramide accumulation in the liver that can be reversed by gut microbiota modulation.","volume":"61","author":"Crescenzo","year":"2017","journal-title":"Food Nutr Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.physbeh.2017.02.027","article-title":"Diet-driven microbiota dysbiosis is associated with vagal remodeling and obesity.","volume":"173","author":"Sen","year":"2017","journal-title":"Physiol Behav."},{"key":"B55","year":"1998","journal-title":"Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline."},{"key":"B56","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/MOL.0b013e3282fee935","article-title":"Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis.","volume":"19","author":"Vance","year":"2008","journal-title":"Curr Opin Lipidol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1139\/o90-079","article-title":"Reduction in VLDL, but not HDL, in plasma of rats deficient in choline.","volume":"68","author":"Yao","year":"1990","journal-title":"Biochem Cell Biol Biochim Biol Cell."},{"key":"B58","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrgastro.2010.191","article-title":"Animal models of nonalcoholic fatty liver disease.","volume":"8","author":"Hebbard","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH.","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatolology."},{"key":"B60","doi-asserted-by":"publisher","first-page":"12511","DOI":"10.1073\/pnas.0601056103","article-title":"Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.","volume":"103","author":"Dumas","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/nu10101398","article-title":"Implication of trimethylamine N-oxide (TMAO) in disease: potential biomarker or new therapeutic target.","volume":"10","author":"Janeiro","year":"2018","journal-title":"Nutrients."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/srep19076","article-title":"Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults.","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nm.3145","article-title":"Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.","volume":"19","author":"Koeth","year":"2013","journal-title":"Nat Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.jbiosc.2014.03.001","article-title":"Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet.","volume":"118","author":"Gao","year":"2014","journal-title":"J Biosci Bioeng."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.3748\/wjg.v24.i23.2468","article-title":"Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.","volume":"24","author":"Ye","year":"2018","journal-title":"World J Gastroenterol."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20020308","article-title":"Intestinal microbiota protects against MCD diet-induced steatohepatitis.","volume":"20","author":"Schneider","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/nu13093135","article-title":"Positive effects of exercise intervention without weight loss and dietary changes in NAFLD-related clinical parameters: a systematic review and meta-analysis.","volume":"13","author":"Babu","year":"2021","journal-title":"Nutrients."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012401","article-title":"Improvement of lipoprotein profile and metabolic endotoxemia by a lifestyle intervention that modifies the gut microbiota in subjects with metabolic syndrome.","volume":"8","author":"Guevara-Cruz","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease.","volume":"69","author":"Wong","year":"2018","journal-title":"J Hepatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/apt.15427","article-title":"Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program.","volume":"50","author":"Huber","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"B71","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1249\/MSS.0000000000002112","article-title":"Exercise training modulates gut microbiota profile and improves endotoxemia.","volume":"52","author":"Motiani","year":"2020","journal-title":"Med Sci Sports Exerc."},{"key":"B72","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cmet.2019.11.001","article-title":"Gut microbiome fermentation determines the efficacy of exercise for diabetes prevention.","volume":"31","author":"Liu","year":"2020","journal-title":"Cell Metab."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1093\/ajcn\/nqab150","article-title":"Effect on gut microbiota of a 1-y lifestyle intervention with Mediterranean diet compared with energy-reduced Mediterranean diet and physical activity promotion: PREDIMED-plus Study.","volume":"114","author":"Muralidharan","year":"2021","journal-title":"Am J Clin Nutr."},{"key":"B74","doi-asserted-by":"publisher","first-page":"547","DOI":"10.7326\/0003-4819-142-7-200504050-00013","article-title":"Meta-analysis: surgical treatment of obesity.","volume":"142","author":"Maggard","year":"2005","journal-title":"Ann Intern Med."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003641.pub3","article-title":"Surgery for obesity.","volume":"2","author":"Colquitt","year":"2009","journal-title":"Cochrane Database Syst Rev."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/nu13082649","article-title":"Bariatric surgery and liver disease: general considerations and role of the gut-liver axis.","volume":"13","author":"Cerreto","year":"2021","journal-title":"Nutrients."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis.","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-020-0122-5","article-title":"Temporospatial shifts in the human gut microbiome and metabolome after gastric bypass surgery.","volume":"6","author":"Ilhan","year":"2020","journal-title":"NPJ Biofilms Microbiomes."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1016\/j.clnu.2018.12.028","article-title":"Fecal bile acid profile after Roux-en-Y gastric bypass and its association with the remission of type 2 diabetes in obese women: a preliminary study.","volume":"38","author":"de Siqueira Cardinelli","year":"2019","journal-title":"Clin Nutr."},{"key":"B80","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s11695-015-1834-0","article-title":"FGF 19 and bile acids increase following Roux-en-Y gastric bypass but not after medical management in patients with type 2 diabetes.","volume":"26","author":"Sachdev","year":"2016","journal-title":"Obes Surg."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.2337\/dc12-2255","article-title":"A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass.","volume":"36","author":"Gerhard","year":"2013","journal-title":"Diabetes Care."},{"key":"B82","doi-asserted-by":"publisher","first-page":"E660","DOI":"10.1002\/oby.20522","article-title":"Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial.","volume":"21","author":"Steinert","year":"2013","journal-title":"Obesity."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.soard.2020.03.013","article-title":"Is bariatric surgery resolving NAFLD via microbiota-mediated bile acid ratio reversal? A comprehensive review.","volume":"16","author":"Talavera-Urquijo","year":"2020","journal-title":"Surg Obes Relat Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s11695-019-03779-7","article-title":"Changes in gut microbiota and hormones after bariatric surgery: a bench-to-bedside review.","volume":"29","author":"Tabasi","year":"2019","journal-title":"Obes Surg."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1007\/s11695-020-04494-4","article-title":"Two bariatric surgical procedures differentially alter the intestinal microbiota in obesity patients.","volume":"30","author":"Chen","year":"2020","journal-title":"Obes Surg."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/nu13082519","article-title":"Long-term effects of bariatric surgery on gut microbiota composition and faecal metabolome related to obesity remission.","volume":"13","author":"Ju\u00e1rez-Fern\u00e1ndez","year":"2021","journal-title":"Nutrients."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2021.2020068","article-title":"The association of weight loss with changes in the gut microbiota diversity, composition, and intestinal permeability: a systematic review and meta-analysis.","volume":"14","author":"Koutoukidis","year":"2022","journal-title":"Gut Microbes."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13367","article-title":"Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery.","volume":"23","author":"Mart\u00ednez-Montoro","year":"2022","journal-title":"Obes Rev."},{"key":"B89","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.soard.2020.08.028","article-title":"Recent advances in the mechanisms underlying the beneficial effects of bariatric and metabolic surgery.","volume":"17","author":"Xu","year":"2021","journal-title":"Surg Obes Relat Dis."},{"key":"B90","doi-asserted-by":"publisher","first-page":"e3004","DOI":"10.1128\/AEM.03004-19","article-title":"Akkermansia muciniphila prevents fatty liver disease, decreases serum triglycerides, and maintains gut homeostasis.","volume":"86","author":"Kim","year":"2020","journal-title":"Appl Environ Microbiol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/gutjnl-2014-308778","article-title":"Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology.","volume":"65","author":"Dao","year":"2016","journal-title":"Gut."},{"key":"B92","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1530\/EJE-17-0403","article-title":"Modulation of the gut microbiome: a systematic review of the effect of bariatric surgery.","volume":"178","author":"Guo","year":"2018","journal-title":"Eur J Endocrinol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.cmet.2015.07.009","article-title":"Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation.","volume":"22","author":"Tremaroli","year":"2015","journal-title":"Cell Metab."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005687","article-title":"Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity.","volume":"5","author":"Liou","year":"2013","journal-title":"Sci Transl Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis.","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care."},{"key":"B96","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.diabet.2019.12.007","article-title":"Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: an updated systematic review of randomized controlled trials.","volume":"46","author":"Mantovani","year":"2020","journal-title":"Diabetes Metab."},{"key":"B97","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.dld.2020.08.021","article-title":"Antidiabetic drugs and non-alcoholic fatty liver disease: a systematic review, meta-analysis and evidence map.","volume":"53","author":"Kumar","year":"2021","journal-title":"Dig Liver Dis."},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01119-3","article-title":"Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH).","volume":"7","author":"Xu","year":"2022","journal-title":"Signal Transduct Target Ther."},{"key":"B99","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2147\/JHC.S277870","article-title":"Gut microbiota, peroxisome proliferator-activated receptors, and hepatocellular carcinoma.","volume":"7","author":"Yu","year":"2020","journal-title":"J Hepatocell Carcinoma."},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111255","article-title":"Crosstalk between PPARs and gut microbiota in NAFLD.","volume":"136","author":"Wu","year":"2021","journal-title":"Biomed Pharmacother."},{"key":"B101","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1126\/science.aam9949","article-title":"Microbiota-activated PPAR-\u03b3 signaling inhibits dysbiotic Enterobacteriaceae expansion.","volume":"357","author":"Byndloss","year":"2017","journal-title":"Science."},{"key":"B102","doi-asserted-by":"publisher","first-page":"E5934","DOI":"10.1073\/pnas.1612559113","article-title":"High-fat diet modifies the PPAR-\u03b3 pathway leading to disruption of microbial and physiological ecosystem in murine small intestine.","volume":"113","author":"Tomas","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104799","article-title":"The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and\/or non-alcoholic steatohepatitis: an up-to date systematic review and meta-analysis of randomized controlled trials.","volume":"159","author":"Jalali","year":"2020","journal-title":"Pharmacol Res."},{"key":"B104","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/dom.14263","article-title":"Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: an analysis of the J-LINK study.","volume":"23","author":"Komorizono","year":"2021","journal-title":"Diabetes Obes Metab."},{"key":"B105","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nm.4345","article-title":"Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug.","volume":"23","author":"Wu","year":"2017","journal-title":"Nat Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.","volume":"64","author":"Armstrong","year":"2016","journal-title":"J Hepatol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes.","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/hep.32235","article-title":"A GLP-1\/GLP-2 receptor dual agonist to treat NASH: targeting the gut-liver axis and microbiome.","volume":"75","author":"Kim","year":"2022","journal-title":"Hepatology."},{"key":"B111","doi-asserted-by":"publisher","first-page":"F824","DOI":"10.1152\/ajprenal.00314.2017","article-title":"Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model.","volume":"315","author":"Mishima","year":"2018","journal-title":"Am J Physiol Renal Physiol."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.15092","article-title":"SGLT-1-specific inhibition ameliorates renal failure and alters the gut microbial community in mice with adenine-induced renal failure.","volume":"9","author":"Ho","year":"2021","journal-title":"Physiol Rep."},{"key":"B113","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/gutjnl-2022-328185","article-title":"Human gut microbiota after bariatric surgery alters intestinal morphology and glucose absorption in mice independently of obesity.","volume":"72","author":"Anh\u00ea","year":"2022","journal-title":"Gut."},{"key":"B114","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1365-2036.2005.02562.x","article-title":"Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis.","volume":"22","author":"Sajjad","year":"2005","journal-title":"Aliment Pharmacol Ther."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1109400","article-title":"Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.","volume":"368","author":"Tang","year":"2013","journal-title":"N Engl J Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.3748\/wjg.v23.i25.4491","article-title":"Eubiotic properties of rifaximin: disruption of the traditional concepts in gut microbiota modulation.","volume":"23","author":"Ponziani","year":"2017","journal-title":"World J Gastroenterol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/MEG.0000000000001232","article-title":"Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot.","volume":"30","author":"Abdel-Razik","year":"2018","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/MEG.0000000000000348","article-title":"Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.","volume":"27","author":"Gangarapu","year":"2015","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B119","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jhep.2022.06.001","article-title":"EASL clinical practice guidelines on the management of hepatic encephalopathy.","volume":"77","year":"2022","journal-title":"J Hepatol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jhep.2021.09.010","article-title":"Rifaximin-\u03b1 reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.","volume":"76","author":"Patel","year":"2022","journal-title":"J Hepatol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/jgh.13841","article-title":"Beneficial effects of rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota.","volume":"33","author":"Jin","year":"2018","journal-title":"J Gastroenterol Hepatol."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155589","article-title":"Effective combination therapy of angiotensin-II receptor blocker and rifaximin for hepatic fibrosis in rat model of nonalcoholic steatohepatitis.","volume":"21","author":"Fujinaga","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B123","doi-asserted-by":"publisher","first-page":"9066","DOI":"10.1073\/pnas.1219451110","article-title":"Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity.","volume":"110","author":"Everard","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.841132","article-title":"Rifaximin ameliorates non-alcoholic steatohepatitis in mice through regulating gut microbiome-related bile acids.","volume":"13","author":"Jian","year":"2022","journal-title":"Front Pharmacol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.dld.2022.04.012","article-title":"Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis.","volume":"54","author":"Enomoto","year":"2022","journal-title":"Dig Liver Dis."},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1177\/1756284819878046","article-title":"Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"12","author":"Tang","year":"2019","journal-title":"Ther Adv Gastroenterol."},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1484598","article-title":"Systematic review with meta-analysis: the effects of probiotics in nonalcoholic fatty liver disease.","volume":"2019","author":"Xiao","year":"2019","journal-title":"Gastroenterol Res Pract."},{"key":"B128","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/10_2015_5008","article-title":"Anaerobic probiotics: the key microbes for human health.","volume":"156","author":"El Enshasy","year":"2016","journal-title":"Adv Biochem Eng Biotechnol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1099\/jmm.0.017541-0","article-title":"Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease.","author":"Van Immerseel","year":"2010","journal-title":"J Med Microbiol."},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-016-0271-6","article-title":"Sub-clinical detection of gut microbial biomarkers of obesity and type 2 diabetes.","volume":"8","author":"Yassour","year":"2016","journal-title":"Genome Med."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-019-0495-2","article-title":"Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study.","volume":"25","author":"Depommier","year":"2019","journal-title":"Nat Med."},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-018-0636-7","article-title":"Technical aspects of fecal microbial transplantation (FMT).","volume":"20","author":"Bhutiani","year":"2018","journal-title":"Curr Gastroenterol Rep."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2217\/fmb-2020-0061","article-title":"Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders.","volume":"15","author":"Ianiro","year":"2020","journal-title":"Future Microbiol."},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10122605","article-title":"Fecal microbiota transplantation in patients with HBV infection or other chronic liver diseases: update on current knowledge and future perspectives.","volume":"10","author":"Paratore","year":"2021","journal-title":"J Clin Med."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/hep4.1601","article-title":"Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis.","volume":"4","author":"Witjes","year":"2020","journal-title":"Hepatol Commun."},{"key":"B136","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1053\/j.gastro.2012.06.031","article-title":"Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome.","volume":"143","author":"Vrieze","year":"2012","journal-title":"Gastroenterology."},{"key":"B137","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/gutjnl-2020-323617","article-title":"Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial.","volume":"71","author":"Ng","year":"2022","journal-title":"Gut."},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial.","volume":"12","author":"Xue","year":"2022","journal-title":"Front Cell Infect Microbiol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/gutjnl-2018-316307","article-title":"Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.","volume":"68","author":"Chu","year":"2019","journal-title":"Gut."},{"key":"B140","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist.","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab."},{"key":"B141","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/liv.13531","article-title":"Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD.","volume":"38","author":"Nobili","year":"2018","journal-title":"Liver Int."},{"key":"B142","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/liv.15463","article-title":"High prevalence of lower limb atherosclerosis is linked with the gut-liver axis in patients with primary biliary cholangitis.","volume":"43","author":"Ponziani","year":"2022","journal-title":"Liver Int."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut."},{"key":"B144","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered bile acid metabolome in patients with nonalcoholic steatohepatitis.","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig Dis Sci."},{"key":"B145","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.metabol.2010.03.006","article-title":"Plasma metabolomic profile in nonalcoholic fatty liver disease.","volume":"60","author":"Kalhan","year":"2011","journal-title":"Metabolism."},{"key":"B146","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/bph.14095","article-title":"Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease.","volume":"175","author":"Wang","year":"2018","journal-title":"Br J Pharmacol."},{"key":"B147","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet."},{"key":"B148","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.","volume":"75","author":"Harrison","year":"2021","journal-title":"J Hepatol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/hep.31523","article-title":"The commensal microbe veillonella as a marker for response to an FGF19 analog in NASH.","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology."}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2023.1110536\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T10:30:33Z","timestamp":1676543433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2023.1110536\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":149,"alternative-id":["10.3389\/fnut.2023.1110536"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2023.1110536","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,16]]},"article-number":"1110536"}}